CN116036146A - 一种用于预防或治疗辐射损伤的组合物及其用途和产品 - Google Patents
一种用于预防或治疗辐射损伤的组合物及其用途和产品 Download PDFInfo
- Publication number
- CN116036146A CN116036146A CN202211326952.3A CN202211326952A CN116036146A CN 116036146 A CN116036146 A CN 116036146A CN 202211326952 A CN202211326952 A CN 202211326952A CN 116036146 A CN116036146 A CN 116036146A
- Authority
- CN
- China
- Prior art keywords
- composition
- preventing
- skin
- spray
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 208000019155 Radiation injury Diseases 0.000 title abstract description 19
- 230000005855 radiation Effects 0.000 claims abstract description 40
- 230000006378 damage Effects 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 15
- 239000004359 castor oil Substances 0.000 claims description 9
- 235000019438 castor oil Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- -1 patch Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- 229940035437 1,3-propanediol Drugs 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 239000000284 extract Substances 0.000 abstract description 24
- 241000219357 Cactaceae Species 0.000 abstract description 23
- 150000004676 glycans Chemical class 0.000 abstract description 20
- 229920001282 polysaccharide Polymers 0.000 abstract description 20
- 239000005017 polysaccharide Substances 0.000 abstract description 20
- 229940102480 bilberry extract Drugs 0.000 abstract description 17
- 235000019209 bilberry extract Nutrition 0.000 abstract description 17
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 abstract description 15
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 abstract description 15
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 abstract description 15
- 229950011318 cannabidiol Drugs 0.000 abstract description 15
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 abstract description 15
- 230000003020 moisturizing effect Effects 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 230000036555 skin type Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- 240000004308 marijuana Species 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 230000000052 comparative effect Effects 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 32
- 241000218236 Cannabis Species 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 8
- 244000078534 Vaccinium myrtillus Species 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 4
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000009120 camo Nutrition 0.000 description 4
- 235000005607 chanvre indien Nutrition 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000011487 hemp Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000005865 ionizing radiation Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000000254 ciliated cell Anatomy 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000002758 humerus Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000000050 nutritive effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 235000016357 Mirtillo rosso Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000001155 Opuntia dillenii Species 0.000 description 1
- 235000006544 Opuntia dillenii Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 1
- 244000077923 Vaccinium vitis idaea Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- DETAHNVSLBCZAA-ARJGXJLFSA-N photo product Chemical compound C[C@@H]([C@]12O)[C@@H](OC(C)=O)[C@@]3(OC(C)=O)C(C)(C)C3[C@@H]2C2[C@]3(COC(C)=O)C[C@]4(O)[C@H]1C2[C@@]3(C)C4=O DETAHNVSLBCZAA-ARJGXJLFSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种用于预防或治疗辐射损伤的组合物,其包含大麻二酚、大麻多糖、仙人掌提取物和越桔提取物。本发明还提供了该组合物的用途及产品。本发明的组合物各成分协同增效,具有较强的预防或治疗辐射损伤的作用,且在皮肤制剂中安全有效,温和,不刺激,清爽补水,适合所有肤质,而且对于受损细胞具有修复的功效。
Description
技术领域
本发明涉及化学领域,具体涉及一种用于预防或治疗辐射损伤的组合物及其用途和产品。
背景技术
随着手机、电脑等等电子设备的逐渐普及,移动基站覆盖面越来越广,不论是工作或者是生活,我们大多数人都离不开电子设备。电子设备给人们带来方便的同时,也带来潜在的危害性,即,辐射。人本身就是一个电导体,就是一个生物弱电磁场,不论我们在室外还是室内都无时无刻免不了皮肤暴露在电磁辐射中。电磁辐射以及自然光中带有的光辐射,会间接引发自由基的产生,自由基增多对我们的皮肤就会有很大的损害。研究表明,辐射危害性的具体表现为使得人体皮肤中的血清抗蛋白酶失去活性,使皮肤的成纤细胞增殖减少,皮肤上病原微生物增多,从而破坏皮肤屏障,细胞膜受损,也会影响正常细胞的增殖分化,细胞膜破坏的速度大于再生的速度,组织的功能就会受到影响,长期辐射的结果就是使得皮肤老化,黑色素增加,炎症因子增加,破坏人体正常的皮肤免疫系统。
目前市场上预防或治疗辐射损伤的成分主要分为两类,一类是有机物,例如蛇毒肽等,还有一些常见的来源于大自然的天然活性成分如虾青素、茶多酚、红景天等,有机物成分属于化学防治辐射损伤;另一类是无机物,例如常见的硫酸钡、银、氧化锌、二氧化钛等,无机物成分属于物理防治辐射损伤。
专利CN 109966160 A公开了一种含天然产物的多重防辐射Pickering乳液及其制备方法,通过添加大豆异黄酮、茶多酚、维生素E、白藜芦醇等天然产物,赋予产品多重防辐射、抗氧化、抗衰老、抗菌等功效,同时具有润肤保健效果。
专利CN 110037953 A公开了一种仙人掌果提取物保湿水及其制备方法,通过将仙人掌果提取物与其他保湿剂复配,其中仙人掌果提取物具有抗氧化作用,制得一种仙人掌果提取物保湿水,具备保湿抗氧化的作用。
专利CN 110882183 A公开了一种抗辐射组合物,主要抗氧化成分包括番茄红素、虾青素、茶多酚,另外加入了透皮吸收促进剂,该抗辐射组合物主要针对日光中紫外线UVA和UVB。
物理防治辐射损伤的产品都是通过添加一定量的二氧化钛及氧化锌,靠反射或散射作用,阻挡紫外线来达到预防或治疗辐射损伤的目的。
现有的大多数产品都是通过物理或者化学的方法来阻隔辐射及紫外线。总体来说,市场上大多数预防或治疗辐射损伤的产品的缺点是在皮肤表面太过厚重油腻,防治辐射损伤的时间只能达到3-4小时,需要隔一段时间就使用一次,尤为繁琐,长期积累对皮肤刺激性很强。因此,研制一种对肌肤安全性高、温和不刺激、清爽补水的预防或治疗辐射损伤的产品是十分必要的。
发明内容
针对这些问题,本发明开发了具有较强的预防或治疗辐射损伤作用的天然植物提取成分,经过筛选及相应的研究,选择最有效果的几种植物提取物复配,组合物各成分协同增效,具有较强的预防或治疗辐射损伤作用,且在皮肤制剂中安全有效,温和,不刺激,轻薄自然,清爽舒适,适合所有肤质,而且对于受损细胞具有修复的功效。本发明组合物可以用于各种制剂中,例如喷雾剂、滴剂、贴剂、软膏剂、水剂、膏霜等制剂。
本发明的目的之一是提供一种用于预防或治疗辐射损伤的组合物,其包含大麻二酚、大麻多糖、仙人掌提取物和越桔提取物。
根据本发明的用于预防或治疗辐射损伤的组合物,其中大麻二酚从大麻中提取获得。大麻(cannabis,cannabis sativa L.)是大麻科(Cannabinaceae)大麻属(cannabis)一年生草本植物,一种古老的植物,我国现存最早的药物学专著《神农本草经》对大麻的功效已经有记录,其具有优越的消炎、镇痛功效。大麻二酚有提升皮肤屏障功能、对抗肌肤炎症、止痒、控油、抑制痤疮的效果,对反复的红肿痘和炎症痘痘,有着超强作用。大麻二酚对皮肤强大修复功效成为国内外护肤品中的佼佼者,但是在国内应用比起其他的提取物来说还不是很广泛,值得研究探索。大麻二酚可以修复成纤细胞,促进细胞的分裂增殖,提升DNA损伤修复能力,促进细胞的自我修复和更新。
根据本发明的用于预防或治疗辐射损伤的组合物,其中大麻多糖也是从大麻中提取获得,属于植物多糖。通过分子内和分子间氢键稳定,形成三维立体网状结构,可在角质层细胞间脂质和糖链之间产生大量相互作用,吸附于皮肤表面,形成弹性粘着连续的生物薄膜,起到修复肌肤屏障的作用。具有免疫调节、抗肿瘤、抗辐射、抗菌、抗氧化、抗病毒、抗疲劳、保湿作用。能够清除自由基增强机体的免疫功能,从而达到保护皮肤的功效,目前在皮肤制剂中应用的较少。
上述大麻多糖是从工业大麻中提取的杂多糖,其制备方法如下:
(1)称取工业大麻花叶原料,加入纯化水,加酸调pH至3.0~3.5,热回流提取1~3h,提取1~3次,合并提取液得大麻多糖初提物;
(2)大麻多糖初提物过树脂柱层析纯化,喷雾干燥,得所述大麻多糖。
优选地,步骤(1)所述工业大麻花叶原料和纯化水的质量体积比为1:5~10;所述酸为甲酸、乙酸、草酸、柠檬酸、盐酸、硝酸、硫酸中的一种或两种以上组合,加酸调节pH可以增加细胞壁通透性,利于多糖浸出。
优选地,步骤(2)中所述树脂柱填料为阴离子交换树脂D900,用量为工业大麻花叶原料质量的1/30-1/100;洗脱溶剂为水,洗脱至流出液近无色,合并收集流出液,喷雾干燥得所述大麻多糖。
根据本发明的用于预防或治疗辐射损伤的组合物,其中仙人掌提取物,英文名称是OPUNTIA DILLENII EXTRACT,仙人掌提取物中含有丰富的人体所需的氨基酸及超氧化物歧化酶(SOD)、多糖以及丰富的维生素C,具有很强的清除自由基的功效。研究表明,仙人掌提取物具有抗氧化、美白、保湿、抗过敏等等的功效。通过强大的清除自由基的功效达到预防或治疗辐射损伤的作用。
仙人掌提取物可以通过市场购买,也可以自制,其制备方法如下:
准备仙人掌清洗晾干,砌成小块状,破壁机打碎成粘液,加入水提取,仙人掌与水的的质量体积比为1:3-4,单位为g/ml,所述仙人掌与水的质量体积比是指仙人掌的质量与溶剂水的体积之比,例如,每g仙人掌采用3~4ml的水进行提取。超声波辅助提取60分钟,温度设置为60℃,得到的提取液于离心管中2000r/min离心5分钟,得到的上清液通过旋转蒸发至溶剂挥发,得到仙人掌提取浓缩液,将浓缩液冷冻干燥,得到粉末,即为仙人掌提取物。
根据本发明的用于预防或治疗辐射损伤的组合物,其中越桔提取物从越桔中提取获得。越桔是一种营养价值非常高的水果,果肉富含丰富的维生素、蛋白质和矿物质等营养元素,其含有一定的糖类、果酸及鞣酸和纤维素,其中越桔中独特的、珍贵的花青素、花色苷在众水果中比重非常高,有很强的抗氧化性,可抗自由基、延缓衰老,且含有大量的维生素C,具有较强的抗氧化功能。越桔提取物对弹性蛋白酶和胶原蛋白酶活性的抑制作用显示,可减缓弹性蛋白和胶原蛋白的降解,可维持皮肤弹性,结合其抗氧化性,可用于抗皱抗老;同时能抑制黑色素细胞的活性,具有一定的美白功效;还能抑制游离的组胺,所以是抗敏抑制剂;同时也有一定的抗炎效果,用作抗炎剂。
越桔提取物可以通过市场购买,也可以自制,其制备方法如下:
准备越桔的果实,破壁机打碎,加入水超声波辅助提取3小时,越桔与水的质量体积比为1:3-4,单位为g/ml,所述越桔与水的质量体积比是指越桔的质量与溶剂水的体积之比,例如,每g越桔采用3~4ml的水进行提取,提取温度为70℃-80℃左右,过滤,得到的滤液于离心管中2000r/min离心10min,得到的上清液通过旋转蒸发至溶剂挥发,得到越桔提取浓缩液,将浓缩液冷冻干燥,得到粉末,即为越桔提取物。
根据本发明的用于预防或治疗辐射损伤的组合物,其中所述组合物按重量计包含以下成分:
根据本发明的用于预防或治疗辐射损伤的组合物,其中所述组合物按重量计包含以下成分:
根据本发明的用于预防或治疗辐射损伤的组合物,其中所述组合物按重量计包含以下成分:
本发明的另一目的是提供上述组合物在制备用于预防或治疗辐射损伤的的药物中的用途。
根据本发明的用途,其中所述组合物在所述药物中的质量分数为1-20%。
根据本发明的用途,其中所述药物为喷雾剂、滴剂、贴剂、软膏剂、水剂、膏霜的形式。
本发明的又一目的是提供一种用于预防或治疗辐射损伤的喷雾剂,其包含上述组合物,所述组合物在所述喷雾剂中的质量分数为1-20%。
根据本发明的喷雾剂,其中所述喷雾剂还包含保湿剂和增溶剂。
根据本发明的喷雾剂,其中所述保湿剂可以为双丙甘醇、甘油聚醚-26、1,3-丙二醇、1,2-己二醇、丁二醇中的一种或多种,优选为双丙甘醇。
根据本发明的喷雾剂,其中所述增溶剂可以为PEG-40氢化蓖麻油、PEG-60氢化蓖麻油、吐温60、吐温40、PPG-13-癸基十四醇聚醚-24、PPG-20-癸基十四醇聚醚-10中的一种或多种,优选为PEG-60氢化蓖麻油。
有益效果
本发明开发了具有较强的预防或治疗辐射损伤作用的天然植物提取成分,经过筛选及相应的研究,选择最有效果的几种植物提取物复配,组合物各成分协同增效,具有较强的预防或治疗辐射损伤的作用,且在皮肤制剂中安全有效,温和,不刺激,清爽补水,适合所有肤质,而且对于受损细胞具有修复的功效。
具体实施方式
以下实施例仅是对本发明予以解释说明,并未对本发明的保护范围进行任何限制。对于本领域技术人员而言,凡未脱离本发明技术精神所作的同等实施方式或变更均在本发明的保护范围之内。
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。
实施例
实施例1
本实施例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖30重量份、仙人掌提取物10重量份、越桔提取物50重量份。
实施例2
本实施例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖3重量份、仙人掌提取物6重量份、越桔提取物4重量份。
实施例3
本实施例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖2重量份、仙人掌提取物0.6重量份、越桔提取物10重量份。
实施例4
本实施例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖0.3重量份、仙人掌提取物3重量份、越桔提取物0.6重量份。
实施例5
本实施例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖5重量份、仙人掌提取物50重量份、越桔提取物30重量份。
对比例1
本对比例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻多糖3重量份、仙人掌提取物6重量份、越桔提取物4重量份。
对比例2
本对比例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、仙人掌提取物6重量份、越桔提取物4重量份。
对比例3
本对比例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖3重量份、越桔提取物4重量份。
对比例4
本对比例提供了一种用于预防或治疗辐射损伤的组合物,包括大麻二酚1重量份、大麻多糖3重量份、仙人掌提取物6重量份。
本发明应用例1-5
提供一种具有预防或治疗辐射损伤功效的喷雾,以质量百分含量计分别含有实施例1-5的组合物10%,保湿剂(双丙甘醇)6%、增溶剂(PEG-60氢化蓖麻油)5%、余量为水,其制备方法如下:
(1)依次称量大麻二酚、双丙甘醇、PEG-60氢化蓖麻油,搅拌混合均均,加入一定量的水(约水总量的三分之一),恒温水浴加热搅拌,其温度为65-75℃,加热时间30min,至溶解为A相;
(2)依次称量大麻多糖、仙人掌提取物、越桔提取物,加入剩余的水,恒温水水浴加热搅拌至溶解均匀,温度为40-45℃,得到B相;
(3)将A相和B相混合均匀后即得。
对比应用例1-4
提供一种具有预防或治疗辐射损伤功效的喷雾,以质量百分含量计分别含有对比例1-4的组合物10%,保湿剂(双丙甘醇)6%、增溶剂(PEG-60氢化蓖麻油)5%、余量为水,其制备方法同本发明应用例1-5。
实验例
实验例1UVB辐照实验:
选用Balb/c小鼠(4~6周),240只,雌性,体重18~22g,购自北京安凯毅博生物技术有限公司,生产许可证:SCXK(京)2017-0006。将小鼠随机分为12组,每组20只,即空白对照组、模型组、溶剂组(去离子水)与实验组(实施例1-5,对比例1-4,分别取实施例和对比例组合物1g,用去离子水和丁二醇质量比为1:2的溶剂配制成浓度0.1g/ml的样品),实验前2d剪去背部脊柱两侧体表长毛,面积约为3.0cm×3.0cm,用8%硫化钠进行脱毛。每次照射前,用改装过的小鼠固定器先固定好小鼠,然后暴露剃毛区,其余非照射部位用防辐射布遮盖。除空白对照组外,对其余各组小鼠进行以下处理:开启UVB紫外线灯,预热15min,固定光源距小鼠背部距离约为20cm,照射时间为40min,照射强度为0.25mW·cm-2,辐照量为600mJ·cm-2;照射期间停止给水给食,照射后0.5h恢复;照射后30min起,开始于照射部位均匀涂抹药物125μL·(10g)-1。模型组除照射UVB外不作其他处理,实验组每天给药1次,连续给药11d,溶剂组给予等体积去离子水。分别于照射后第1、2、4、7、11d的5个时相点,每组每次处死4只小鼠,取小鼠背部晒伤处皮肤全层,无菌刀片去除皮下组织。
取照射处皮肤约100mg,滤纸吸去血迹,称重,放入0.9%氯化钠溶液中,按100mg组织加1mL0.9%氯化钠溶液的比例碾磨制成匀浆。4℃,10000r·min-1条件下离心15min,将离心好的匀浆留上清液丢弃沉淀,置于-80℃保存。采用ELISA法检测皮肤组织上清液中8-OHdG、IL-6和NF-κB的含量,具体操作步骤按试剂盒说明书要求进行。
表1辐照后不同时间点皮肤组织中8-OHdG水平
在整个观察周期中,除空白对照组处于稳定值,其他组8-OHdG含量总体呈上升趋势。与空白对照组比较,模型组8-OHdG含量显著升高(P<0.01),而在第1、2、4、7、11天5个时相点,实施例1-5组8-OHdG含量均显著低于模型组和溶剂组(P<0.05,P<0.01),表明本发明组合物在UVB辐照损伤后能够有效减少皮肤中光产物8-OHdG的堆积,实施例1-5组与对比例1-4相比,说明本发明组合物组合后具有协同增效作用。
表2辐照后不同时间点皮肤组织中IL-6水平
在整个观察周期中,空白对照组IL-6含量总体呈下降趋势。与空白对照组比较,其他组IL-6含量显著升高(P<0.01),实施例1-5组IL-6含量均显著低于模型组和溶剂组(P<0.05,P<0.01),表明本发明组合物可以增强UVB辐照损伤机体抑制炎症因子释放的能力,实施例1-5组与对比例1-4相比,说明本发明组合物组合后可以协同抑制炎症因子的释放。
表3辐照后不同时间点皮肤组织中NF-κB水平
在辐射损伤初期,各组组织中NF-κB水平差异较大,随着时间延续,空白对照组NF-κB水平比较平稳。其他组小鼠皮肤NF-κB水平呈下降趋势,且差异变小;与空白对照组比较,模型组在辐照初期NF-κB水平显著升高(P<0.01);实施例1-5组与模型组相比,实施例1-5组NF-κB水平明显低于模型组,实施例1-5组与对比例1-4组相比,说明本发明组合物组合后能够更好地抑制NF-κB,减轻细胞的炎症反应。提示本发明组合物在辐射损伤早期对NF-κB抑制作用明显。
实验例2
从液氮罐中取出保存的HaCaT细胞冻存管,待液氮蒸发完,迅速放入已预热好的37℃恒温水浴锅中快速解冻。完全解冻后,75%酒精擦拭冻存管外壁后于超净台中进行,将细胞液转移至离心管,离心机500rpm离心5min。待看到明显细胞团后,轻轻吸除上清液,加入1ml新鲜的10%DMEM细胞培养液,移液枪小心吹打,使其成细胞悬液。将细胞悬液全部转移至细胞培养瓶中,置于37℃、5%CO2培养箱孵育,每12h换液一次,每日定时观察细胞生长状况,待细胞贴壁达80%-90%时,可用于细胞传代。
倒置显微镜下观察细胞生长状态,待细胞贴壁达80%-90%时,吸弃旧培养液,用2ml PBS缓冲液洗涤2次。加入0.25%胰蛋白酶溶液1ml,使其均匀没过细胞,置于37℃、5%CO2培养箱消化3min。倒置显微镜下观察细胞变圆后,加入3ml的含有胎牛血清的DMEM培养液终止消化,小心吹打混匀,使细胞脱落。将细胞悬液转移至离心管中,1000rpm离心5min。弃上清液,加入新培养液重悬细胞,细胞培养瓶中,加入新鲜的10%DMEM培养液补齐7ml,置于37℃、5%CO2培养箱中进行培养。
倒置显微镜下观察细胞形态及生长状况,取对数生长期细胞,弃掉旧培养液,PBS洗涤2遍。加入胰蛋白酶消化,倒置显微镜下看到细胞变圆后,弃掉胰蛋白酶溶液,加入含10%FBS的DMEM培养液终止消化。将细胞悬液转移至离心管中,1000rpm离心5min。弃上清液,加入配制好的细胞冻存液(含90%胎牛血清和10%DMSO),小心吹打混匀。细胞计数后,每个冻存管加1ml细胞悬液,在冷冻管上标记时间、细胞名称,放入冻存盒,-80℃冰箱放置48h后移至液氮罐长期保存。
根据实验设计分为空白对照组、溶剂组、实施例1、实施例2、实施例3、实施例4、实施例5、对比例1、对比例2、对比例3、对比例4(分别取实施例和对比例组合物1g,用去离子水和丁二醇质量比为1:2的溶剂配制成浓度0.1g/ml的样品)。
取对数生长期HaCaT细胞,弃旧培养液,PBS洗涤3次,加入0.25%胰蛋白酶消化后制成浓度为3x104个/ml的细胞悬液。接种于96孔板,每孔2ml细胞悬液,置于37℃、5%CO2培养箱孵育。24h后倒置显微镜下观察细胞是否贴壁,细胞贴壁后,分成两组加入上述各种样品50μl(溶剂组加入同体积溶剂),一组加入样品2h后37℃、5%CO2培养箱中进行培养24h。另一组加入药物2h后进行电离辐照20Gy。辐照后,37℃、5%CO2培养箱中进行培养24h。于每孔加入10ul CCK-8溶液,置于培养箱内继续孵育2h。酶标仪检测波长450nm处OD值,并计算细胞存活率。为确保精确,实验重复3次。
由表4可见,HaCaT细胞经20Gy电离辐射后细胞活力明显降低,经过各组药物处理2小时后经培养,细胞存活率均有不同的提升,于20Gy电离辐射后经培养检测,实施例组与对比例组,细胞存活数量增加,其中实施例组优于对比例组,实施例3组细胞存活率更高。
表4电离辐射后细胞活力
实验例3抗紫外线的损伤实验:MTT法检测HaCaT细胞增殖的影响
细胞复苏及传代:将液氮冻存HaCaT细胞取出至于37±2℃水浴锅中摇晃至融化后转移至25mm2含有5ml DMEM培养基的培养皿中,于5%CO2%培养箱中37℃静置培养,培养24h后更换培养基,当HaCaT细胞融合至80%-90%时,用2ml配置好的1xPBS缓冲液洗涤细胞3次,加入0.25%胰酶消化,培养箱中继续放置10min后取出,显微镜下观察,当有80-90%细胞变圆10-20%自动脱落时加入培养基4ml终止消化。将得到的液体转移至15ml离心管中离心(1000rpm、3min)后,倒掉上清液后加入2ml DMEM培养基悬浮细胞,以事适宜的浓度接种至培养皿,加入DMEM培养基,使培养基总体积为6ml,继续至于培养箱中培养,每2-3d换液1次,每5-6d按需要传代。选择生长旺盛,形态良好的细胞用于实验。
HaCaT细胞用含10%胎小牛血清的培养液配成单个细胞悬液,以1x104个/孔接种到96孔板,每孔体积约为100μl,培养24小时,待细胞融合后,将各组培养细胞的培养液吸尽,PBS冲洗两次,在底部加少量的PBS(30μl)覆盖细胞,并以90MJ/cm2UVB的剂量照射,正常组不辐照,辐照光源与细胞的垂直距离为20cm,照射时间为60min,照射时培养板置于厚纱布包裹的冰袋上,避免照射后过热。照射以后吸去PBS,根据实验分组再加入培养基或者含有不同组合物样品的新鲜培养基,继续培养24h后,每孔加入MTT溶液10μl(5mg/ml)后至于培养箱内孵育4h后取出,吸去上清液,每孔加入150μl DMSO低速震荡15min,于酶联免疫检测仪上测定吸光度,检测波长570nm,细胞增殖活力以样品空白为基准计算,计算细胞的增殖活力。分组为:正常组(不照光,只加1%DMSO),模型组(照光,加1%DMSO),实验组(共9组,分别含实施例1-5及对比例1-4组合物0.01g/ml)
表5
组别 | 细胞增殖活力(%) |
正常组 | 135.56 |
模型组 | 100.00 |
实施例1 | 120.34 |
实施例2 | 128.25 |
实施例3 | 128.08 |
实施例4 | 118.65 |
实施例5 | 119.89 |
对比例1 | 110.21 |
对比例2 | 109.89 |
对比例3 | 110.23 |
对比例4 | 111.75 |
从表5结果能看出,模型组与正常组相比细胞活力降低,说明辐照后造成了细胞损伤,与模型组相比,实施列及对比例得到的组合物对紫外线照射后的细胞均有促进增殖作用,但是明显能看出实施例1-5增殖作用强于对比例1-4,说明本发明组合物对紫外线辐射后的细胞损伤具有修复作用,且本发明组合物组合具有协同增效作用,其中实施例2配比用量的组合物最优。
实验例4防辐射损伤的体外功能评价实验
随机选择不同肤质的100名受试者,随机分成10组,对应喷涂实施例1-5和对比例1-4得到的组合物,对照组用生理盐水代替。在受试者手臂肱骨区域喷涂2g左右,均匀喷涂,然后用紫外灯,型号为UVA-340,在远离70cm的距离处照射手臂肱骨区域5min后,使用精密仪器测量受试者皮肤的温度,通过温差的大小来判定抗辐射的能力,取每组十个人的平均值作为考察。实验结果如表6所示。
表6实验前后受试部位的温度变化
组别 | 紫外照射前(℃) | 紫外照射后(℃) | 紫外照射前后温差(℃) |
实施例1 | 30.5 | 33.0 | 2.5 |
实施例2 | 30.9 | 32.0 | 1.1 |
实施例3 | 29.8 | 32.2 | 2.4 |
实施例4 | 30.1 | 32.6 | 2.5 |
实施例5 | 30.9 | 32.9 | 2.0 |
对比例1 | 31.2 | 32.9 | 1.7 |
对比例2 | 30.1 | 34.9 | 4.8 |
对比例3 | 30.3 | 33.9 | 3.6 |
对比例4 | 30.8 | 33.8 | 3.0 |
对照组 | 29.2 | 36.9 | 7.7 |
表6中通过紫外线照射后的温差能看出,实施例及对比例组合物都具有一定的防辐射损伤的效果,但是本发明实施例组合物的特定种类及添加量的搭配,防辐射损伤的协同效果更好,照射前后温度变化相对对比例更小,和对照组形成了鲜明的对比,说明本发明组合物的复配获得了极佳的防辐射损伤效果。
实验例5清爽补水评价实验
随机选择年龄在25-50岁之间的女性100名,平均分成10组,每组10人,分别使用实施例1-5和对比例1-4得到的喷雾,对照组用生理盐水代替。测试肤感及清爽补水性能,测试区域选择每个人的额头部位,选择固定位置,固定区域2平方厘米做测试,正常的生活环境下25℃、相对湿度65%RH,通过Corneometer CM820皮肤水分测试仪对使用前皮肤做相对应的水分测试,测试结果记录为MMV1,然后对每组人群进行试用,每天上午一次,下午一次,连续用21天,最后一天测试使用最后一次后皮肤的含水量,以MMV2表示。且分别对清爽舒适感打分,清爽舒适感很好为90分以上、清爽舒适感一般为80分以上、清爽舒适感较差为70分以上,最后统计每组的平均值。实验结果如表7所示。
表7
通过表7可以看出不管是对比例还是实施例均有较好的补水效果,用完21天以后,皮肤的含水量检测均有较明显的提高,且使用完成以后,对其舒适感及清爽度的评分均在80分以上,绝大多数人感觉还是很舒服的。
Claims (9)
3.如权利要求1或2所述的组合物在制备用于预防或治疗辐射损伤的药物中的用途。
4.根据权利要求3所述的用途,其中,所述组合物在所述药物中的质量分数为1-20%。
5.根据权利要求3所述的用途,其中,所述药物为喷雾剂、滴剂、贴剂、软膏剂、水剂、膏霜的形式。
6.一种用于预防或治疗辐射损伤的喷雾剂,其包含如权利要求1或2所述的组合物,所述组合物在所述喷雾剂中的质量分数为1-20%。
7.根据权利要求6所述的喷雾剂,其中,所述喷雾剂还包含保湿剂和增溶剂。
8.根据权利要求7所述的喷雾剂,其中,所述保湿剂为双丙甘醇、甘油聚醚-26、1,3-丙二醇、1,2-己二醇、丁二醇中的一种或多种,优选为双丙甘醇。
9.根据权利要求7所述的喷雾剂,其中,所述增溶剂为PEG-40氢化蓖麻油、PEG-60氢化蓖麻油、吐温60、吐温40、PPG-13-癸基十四醇聚醚-24、PPG-20-癸基十四醇聚醚-10中的一种或多种,优选为PEG-60氢化蓖麻油。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111261062 | 2021-10-28 | ||
CN2021112610624 | 2021-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116036146A true CN116036146A (zh) | 2023-05-02 |
Family
ID=86132148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211326952.3A Pending CN116036146A (zh) | 2021-10-28 | 2022-10-25 | 一种用于预防或治疗辐射损伤的组合物及其用途和产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116036146A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101102746A (zh) * | 2005-01-11 | 2008-01-09 | 丁世荣 | 包含笃斯越桔提取物的用于改善皮肤状况的组合物及其制备方法 |
CN110201019A (zh) * | 2019-07-17 | 2019-09-06 | 李卫 | 一种用于治疗肌肉痉挛的含有大麻二酚的组合物及其制备方法 |
WO2019186544A1 (en) * | 2018-03-26 | 2019-10-03 | Raphael Luxenbourg | Topical cannabidiol compositions and methods for protecting the skin from ultra-violet radiation |
CN110711161A (zh) * | 2019-11-03 | 2020-01-21 | 广州悦荟化妆品有限公司 | 一种免洗型的舒敏修护精华面膜 |
CN111494466A (zh) * | 2020-01-14 | 2020-08-07 | 四川大学华西医院 | 一种含大麻提取物的外用组合物及其应用 |
CN111956535A (zh) * | 2019-12-30 | 2020-11-20 | 云南汉盟制药有限公司 | 一种调理剂组合物及其制备方法与应用 |
CN111978417A (zh) * | 2019-09-06 | 2020-11-24 | 云南汉盟制药有限公司 | 一种大麻多糖的提取方法及其产品和应用 |
CN112451439A (zh) * | 2020-12-04 | 2021-03-09 | 云南汉盟制药有限公司 | 含有大麻二酚的皮肤调理组合物和护肤品 |
-
2022
- 2022-10-25 CN CN202211326952.3A patent/CN116036146A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101102746A (zh) * | 2005-01-11 | 2008-01-09 | 丁世荣 | 包含笃斯越桔提取物的用于改善皮肤状况的组合物及其制备方法 |
WO2019186544A1 (en) * | 2018-03-26 | 2019-10-03 | Raphael Luxenbourg | Topical cannabidiol compositions and methods for protecting the skin from ultra-violet radiation |
CN110201019A (zh) * | 2019-07-17 | 2019-09-06 | 李卫 | 一种用于治疗肌肉痉挛的含有大麻二酚的组合物及其制备方法 |
CN111978417A (zh) * | 2019-09-06 | 2020-11-24 | 云南汉盟制药有限公司 | 一种大麻多糖的提取方法及其产品和应用 |
CN110711161A (zh) * | 2019-11-03 | 2020-01-21 | 广州悦荟化妆品有限公司 | 一种免洗型的舒敏修护精华面膜 |
CN111956535A (zh) * | 2019-12-30 | 2020-11-20 | 云南汉盟制药有限公司 | 一种调理剂组合物及其制备方法与应用 |
CN111494466A (zh) * | 2020-01-14 | 2020-08-07 | 四川大学华西医院 | 一种含大麻提取物的外用组合物及其应用 |
CN112451439A (zh) * | 2020-12-04 | 2021-03-09 | 云南汉盟制药有限公司 | 含有大麻二酚的皮肤调理组合物和护肤品 |
Non-Patent Citations (2)
Title |
---|
李观丽, 等: "大麻成分提取工艺综述", 化工技术与开发, vol. 49, no. 05, pages 34 - 39 * |
梁亦龙, 等: "仙人掌对辐射小鼠bcl-2和p53基因表达影响", 时珍国医国药, no. 12, pages 2948 - 2949 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108670943A (zh) | 一种保湿、美白、淡斑植物提取物组合物 | |
WO2021103581A1 (zh) | 具有促进伤口愈合和/或疤痕修复功效的皮肤外用组合物 | |
AU2012286357A1 (en) | Eucommia extract, preparation method therefor and use thereof | |
CN111494466A (zh) | 一种含大麻提取物的外用组合物及其应用 | |
CN101606898B (zh) | 五味子提取物在制备防晒护肤品中的应用 | |
CN109833431A (zh) | 一种抑菌凝胶及其制备方法 | |
US10973755B2 (en) | Method for treating skin aging and photodamage by using Camellia sinensis callus extract | |
CN104547288B (zh) | 具有清除自由基祛红肿功效的外用中药组合物、制剂及其制备方法 | |
CN112656734A (zh) | 一种蒲公英提取物的制备方法、其提取物及应用 | |
CN106620633A (zh) | 肿瘤患者用皮肤修护乳及其制作方法 | |
CN113876626B (zh) | 一种对蓝光诱导皮肤细胞损伤具有保护作用的组合物及其在化妆品中的应用 | |
CN116036146A (zh) | 一种用于预防或治疗辐射损伤的组合物及其用途和产品 | |
CN115429725B (zh) | 用于抗氧化、抗炎、皮肤镇静的化妆品组合物 | |
CN109364290A (zh) | 一种薰衣草精油脂质体液体创可贴及其制备方法 | |
KR101778746B1 (ko) | 인간 중간엽줄기세포의 분화 촉진용 조성물 | |
CN108078868A (zh) | 一种用于护肤品的抗过敏组合物 | |
CN106853204A (zh) | 肿瘤患者用皮肤修护喷雾及其制作方法 | |
CN113576970A (zh) | 一种抗衰老植物提取组合物及其制备与应用 | |
GÜRLEK KISACIK et al. | Effectiveness of bitter melon extract in the treatment of ischemic wounds in rats. | |
CN111714396A (zh) | 一种含依克多因的组合物及其在激光美容中的应用 | |
Kisacik et al. | Effectiveness of bitter melon extract in the treatment of ischemic wounds in rats | |
KR101663971B1 (ko) | 인간 중간엽줄기세포의 분화 촉진용 조성물 | |
CN108113916B (zh) | 一种天然修复肽面膜液及其制备方法 | |
CN114886794B (zh) | 一种具有抗炎和抗氧化作用的组合物及其应用 | |
CN111714395B (zh) | 一种银杏提取物复配的多肽组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |